EcoDrugPlus

Phosphodiesterase 4b

Ensembl ID : ENSORLG00000009796
Gene Symbol: PDE4B
4 Cross references
228 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSORLG00000004643
Gene Symbol: PDE4D
4 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSORLG00000020785
Gene Symbol: PDE5AB
4 Cross references
221 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSORLG00000008573
Gene Symbol: PDE7A
4 Cross references
227 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSORLG00000016583
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:

Phosphoinositide 3-Kinase Regulatory Subunit 5

Ensembl ID : ENSORLG00000015305
Gene Symbol: LOC101155772
3 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSORLG00000013341
Gene Symbol: PIK3R3
4 Cross references
170 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSORLG00000010655
Gene Symbol: PIK3R3
4 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSORLG00000003122
Gene Symbol: PIK3R5
4 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSORLG00000002670
Gene Symbol: PIK3R1
4 Cross references
202 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSORLG00000024365
Gene Symbol: PLA2G10
4 Cross references
232 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSORLG00000015947
Gene Symbol: PLA2G7
4 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).